176 related articles for article (PubMed ID: 28366653)
1. Preformulation investigation and challenges; salt formation, salt disproportionation and hepatic recirculation.
Sigfridsson K; Nilsson L; Ahlqvist M; Andersson T; Granath AK
Eur J Pharm Sci; 2017 Jun; 104():262-272. PubMed ID: 28366653
[TBL] [Abstract][Full Text] [Related]
2. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
[TBL] [Abstract][Full Text] [Related]
3. Salt formation improved the properties of a candidate drug during early formulation development.
Sigfridsson K; Ahlqvist M; Lindsjö M; Paulsson S
Eur J Pharm Sci; 2018 Jul; 120():162-171. PubMed ID: 29730322
[TBL] [Abstract][Full Text] [Related]
4. The crystalline salt form of a selected candidate drug showed photo-, thermal- and humidity induced form transitions.
Sigfridsson K; Lindsjö M; Paulsson S
Eur J Pharm Sci; 2019 Feb; 128():128-136. PubMed ID: 30502453
[TBL] [Abstract][Full Text] [Related]
5. A preformulation evaluation of a photosensitive surface active compound, explaining concentration dependent degradation.
Sigfridsson K; Carlsson KE
Eur J Pharm Sci; 2017 Nov; 109():650-656. PubMed ID: 28736127
[TBL] [Abstract][Full Text] [Related]
6. Preformulation evaluation of AZD1305, an oxabispidine intended for oral and intravenous treatment.
Sigfridsson K; Lundqvist R; Ohlson K
Drug Dev Ind Pharm; 2012 Jan; 38(1):19-31. PubMed ID: 21707325
[TBL] [Abstract][Full Text] [Related]
7. A case study where pharmaceutical salts were used to address the issue of low in vivo exposure.
Sigfridsson K; Ulvinge ML; Svensson L; Granath AK
Drug Dev Ind Pharm; 2019 Feb; 45(2):202-211. PubMed ID: 30256689
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches.
Fakes MG; Vakkalagadda BJ; Qian F; Desikan S; Gandhi RB; Lai C; Hsieh A; Franchini MK; Toale H; Brown J
Int J Pharm; 2009 Mar; 370(1-2):167-74. PubMed ID: 19100319
[TBL] [Abstract][Full Text] [Related]
9. Impact of Solid-State Form on the Disproportionation of Miconazole Mesylate.
Patel MA; Luthra S; Shamblin SL; Arora K; Krzyzaniak JF; Taylor LS
Mol Pharm; 2018 Jan; 15(1):40-52. PubMed ID: 29202237
[TBL] [Abstract][Full Text] [Related]
10. Effect of counterions on the properties of amorphous atorvastatin salts.
Sonje VM; Kumar L; Puri V; Kohli G; Kaushal AM; Bansal AK
Eur J Pharm Sci; 2011 Nov; 44(4):462-70. PubMed ID: 21907794
[TBL] [Abstract][Full Text] [Related]
11. Preformulation study of a poorly water-soluble drug, alpha-pentyl-3-(2-quinolinylmethoxy)benzenemethanol: selection of the base for dosage form design.
Serajuddin AT; Sheen PC; Mufson D; Bernstein DF; Augustine MA
J Pharm Sci; 1986 May; 75(5):492-6. PubMed ID: 3735089
[TBL] [Abstract][Full Text] [Related]
12. Crystal forms of the hydrogen oxalate salt of o-desmethylvenlafaxine.
Dichiarante E; Curzi M; Giaffreda SL; Grepioni F; Maini L; Braga D
J Pharm Pharmacol; 2015 Jun; 67(6):823-9. PubMed ID: 25644936
[TBL] [Abstract][Full Text] [Related]
13. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
[TBL] [Abstract][Full Text] [Related]
14. An investigation into the influence of counterion on the properties of some amorphous organic salts.
Towler CS; Li T; Wikström H; Remick DM; Sanchez-Felix MV; Taylor LS
Mol Pharm; 2008; 5(6):946-55. PubMed ID: 19434850
[TBL] [Abstract][Full Text] [Related]
15. Preformulation characterization and in vivo absorption in beagle dogs of JFD, a novel anti-obesity drug for oral delivery.
Fan Y; Yang M; Wang Y; Li Y; Zhou Y; Chen X; Shan L; Wei J; Gao C
Drug Dev Ind Pharm; 2015 May; 41(5):801-11. PubMed ID: 24694186
[TBL] [Abstract][Full Text] [Related]
16. Early development evaluation of AZD2738, a substrate for the NK receptors.
Sigfridsson K; Ahlqvist M; Lindsjö M; Paulsson S
Drug Dev Ind Pharm; 2011 Jun; 37(6):719-26. PubMed ID: 21323487
[TBL] [Abstract][Full Text] [Related]
17. Disproportionation of a crystalline citrate salt of a developmental pharmaceutical compound: characterization of the kinetics using pH monitoring and online Raman spectroscopy plus quantitation of the crystalline free base form in binary physical mixtures using FT-Raman, XRPD and DSC.
Skrdla PJ; Zhang D
J Pharm Biomed Anal; 2014 Mar; 90():186-91. PubMed ID: 24378612
[TBL] [Abstract][Full Text] [Related]
18. Impact of counterion on the chemical stability of crystalline salts of procaine.
Guerrieri P; Jarring K; Taylor LS
J Pharm Sci; 2010 Sep; 99(9):3719-30. PubMed ID: 19967781
[TBL] [Abstract][Full Text] [Related]
19. Drug salt formation via mechanochemistry: the case study of vincamine.
Hasa D; Perissutti B; Cepek C; Bhardwaj S; Carlino E; Grassi M; Invernizzi S; Voinovich D
Mol Pharm; 2013 Jan; 10(1):211-24. PubMed ID: 23186380
[TBL] [Abstract][Full Text] [Related]
20. Salt Disproportionation in the Solid State: Role of Solubility and Counterion Volatility.
Thakral NK; Behme RJ; Aburub A; Peterson JA; Woods TA; Diseroad BA; Suryanarayanan R; Stephenson GA
Mol Pharm; 2016 Dec; 13(12):4141-4151. PubMed ID: 27766882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
